Loading…
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $747M | $-4M | $-45M | $35M | -29.2% | 26.2% | -60.7% |
| 2024 | $592M | $-74M | $-113M | $-46M | -124.6% | 20.1% | -8.2% |
| 2023 | $493M | $-97M | $-123M | $-91M | -58.7% | 19.9% | 6.2% |
| 2022 | $411M | $-92M | $-116M | $-53M | -48.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 410.92 | 492.68 | 591.84 | 747.14 |
| Operating Revenue | - | 410.92 | 492.68 | 591.84 | 747.14 |
| Cost Of Revenue | - | 129.29 | 160.88 | 184.31 | 219.89 |
| Gross Profit | - | 281.63 | 331.81 | 407.53 | 527.25 |
| Operating Expense | - | 368.81 | 445.89 | 522.40 | 580.20 |
| Research And Development | - | 46.61 | 60.24 | 103.83 | 87.65 |
| Selling General And Administration | - | 322.20 | 385.64 | 418.56 | 492.55 |
| Total Expenses | - | 498.10 | 606.76 | 706.70 | 800.09 |
| Operating Income | - | -87.18 | -114.08 | -114.86 | -52.95 |
| Total Operating Income As Reported | - | -113.78 | -125.16 | -115.50 | -57.41 |
| EBITDA | - | -92.14 | -96.86 | -74.13 | -3.96 |
| Normalized EBITDA | - | -65.53 | -85.78 | -65.90 | 0.49 |
| EBIT | - | -111.75 | -119.01 | -99.90 | -30.44 |
| Interest Income | - | 2.35 | 6.35 | 21.94 | 21.52 |
| Interest Expense | - | 4.14 | 3.65 | 12.82 | 13.15 |
| Net Interest Income | - | -1.79 | 2.70 | 9.12 | 8.37 |
| Other Non Operating Income Expenses | - | -0.31 | -0.20 | 1.25 | 5.44 |
| Other Income Expense | - | -26.92 | -11.28 | -6.98 | 0.98 |
| Interest Income Non Operating | - | 2.35 | 6.35 | 21.94 | 21.52 |
| Interest Expense Non Operating | - | 4.14 | 3.65 | 12.82 | 13.15 |
| Net Non Operating Interest Income Expense | - | -1.79 | 2.70 | 9.12 | 8.37 |
| Pretax Income | - | -115.89 | -122.66 | -112.72 | -43.60 |
| Tax Provision | - | 0.27 | 0.75 | 0.56 | 0.95 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -5.59 | -2.33 | -1.73 | -0.94 |
| Net Income Continuous Operations | - | -116.16 | -123.41 | -113.29 | -44.55 |
| Net Income From Continuing And Discontinued Operation | - | -116.16 | -123.41 | -113.29 | -44.55 |
| Net Income From Continuing Operation Net Minority Interest | - | -116.16 | -123.41 | -113.29 | -44.55 |
| Net Income | - | -116.16 | -123.41 | -113.29 | -44.55 |
| Net Income Common Stockholders | - | -116.16 | -123.41 | -113.29 | -44.55 |
| Net Income Including Noncontrolling Interests | - | -116.16 | -123.41 | -113.29 | -44.55 |
| Normalized Income | - | -95.13 | -114.65 | -106.79 | -41.03 |
| Diluted NI Availto Com Stockholders | - | -116.16 | -123.41 | -113.29 | -44.55 |
| Basic Average Shares | - | 29.92 | 30.53 | 31.20 | 32 |
| Diluted Average Shares | - | 29.92 | 30.53 | 31.20 | 32 |
| Reconciled Depreciation | - | 19.61 | 22.14 | 25.78 | 26.48 |
| Reconciled Cost Of Revenue | - | 129.29 | 160.88 | 184.31 | 219.89 |
| Total Unusual Items | - | -26.61 | -11.08 | -8.23 | -4.46 |
| Total Unusual Items Excluding Goodwill | - | -26.61 | -11.08 | -8.23 | -4.46 |
| Special Income Charges | - | -26.61 | -11.08 | -8.23 | -4.46 |
| Other Special Charges | - | - | - | 7.59 | 3.04 |
| Write Off | - | 0 | 0 | 0.64 | - |
| Impairment Of Capital Assets | - | 23.16 | 11.08 | 0.64 | 4.46 |
| Restructuring And Mergern Acquisition | 0 | 3.44 | 0 | 0 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| iRhythm Holdings, Inc.this co. | IRTC | $3.5B | -79.19 | 23.10 | -29.2% | -1014.62 |
| Oruka Therapeutics, Inc. | ORKA | $3.8B | - | 9.90 | -22.5% | - |
| Crinetics Pharmaceuticals, Inc. | CRNX | $3.7B | -7.85 | 3.68 | -46.9% | -7.02 |
| Beam Therapeutics Inc. | BEAM | $3.4B | -42.24 | 2.73 | -6.5% | -8.96 |
| Tango Therapeutics, Inc. | TNGX | $3.2B |
| - |
| - |
| - |
| - |
| - |
| - |
| -31.54 |
| 9.26 |
| -29.3% |
| -28.67 |
| Denali Therapeutics Inc. | DNLI | $3.2B | -6.24 | 3.15 | -50.6% | -5.60 |
| Haemonetics Corporation | HAE | $3.2B | 32.62 | 3.99 | 12.2% | 15.47 |
| Relay Therapeutics, Inc. | RLAY | $3.2B | -11.46 | 5.59 | -48.8% | -10.42 |
| Option Care Health, Inc. | OPCH | $3.2B | 15.18 | 2.38 | 15.6% | 10.27 |
| Peer Median | - | -7.85 | 3.83 | -25.9% | -7.02 | |